Compare HUT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | LEGN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2023 | 2020 |
| Metric | HUT | LEGN |
|---|---|---|
| Price | $106.37 | $29.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $65.20 | $61.33 |
| AVG Volume (30 Days) | ★ 4.8M | 2.3M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $235,118,000.00 | N/A |
| Revenue This Year | $161.69 | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $14.74 | $16.24 |
| 52 Week High | $112.26 | $45.30 |
| Indicator | HUT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 65.66 |
| Support Level | $46.25 | $25.01 |
| Resistance Level | $112.26 | $29.69 |
| Average True Range (ATR) | 8.73 | 2.17 |
| MACD | -0.53 | -0.12 |
| Stochastic Oscillator | 82.93 | 82.32 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.